Abstract
Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.
Keywords: platelet activation, endothelial activation, target organ damage, Hypertension
Current Pharmaceutical Design
Title: Target Organ Damage in Hypertension: Pathophysiology and Implications for Drug Therapy
Volume: 12 Issue: 13
Author(s): Sunil K. Nadar, Muzahir H. Tayebjee, Franz Messerli and Gregory Y.H. Lip
Affiliation:
Keywords: platelet activation, endothelial activation, target organ damage, Hypertension
Abstract: Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.
Export Options
About this article
Cite this article as:
Nadar K. Sunil, Tayebjee H. Muzahir, Messerli Franz and Lip Y.H. Gregory, Target Organ Damage in Hypertension: Pathophysiology and Implications for Drug Therapy, Current Pharmaceutical Design 2006; 12 (13) . https://dx.doi.org/10.2174/138161206776843368
DOI https://dx.doi.org/10.2174/138161206776843368 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology Association of Serum Uric Acid and Metabolic Syndrome in Type 2 Diabetes
Current Diabetes Reviews Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets Mitochondria Damage in the Pathogenesis of Diabetic Retinopathy and in the Metabolic Memory Associated with its Continued Progression
Current Medicinal Chemistry Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology Foreword:
Current Pharmaceutical Design Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology Separation of Bioactive Peptides by Membrane Processes: Technologies and Devices
Recent Patents on Biotechnology (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry The Vascular Component of Alzheimer`s Disease
Current Neurovascular Research Targeted Therapy of Breast Cancer
Current Pharmaceutical Design Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine
Current Drug Metabolism Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Editorial [Hot topic: Updates on Therapeutic Approaches to Inflammatory Skin Diseases: From Molecular Targets to Drug Development. Part II (Guest Editors: L. Korkina & S. Pastore)]
Current Drug Metabolism Development of Enzyme-Linked Immunosorbent Assay System for PEDF and its Clinical Utility
Current Molecular Medicine Angiotensin-(1-7): Blood, Heart, and Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents